Skip to main content

Cellular Research Precise Targeted RNASeq Assays

Cellular Research has launched its Precise targeted RNAseq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels for oncology, induced pluripotent stem cells, and immunology. The assays use next-generation sequencing alongside the company's Molecular Indexing technology as an alternative to qPCR. The assays are available in 96- and 384-sample formats, enabling customers to sequence up to 4,608 samples in a single sequencing run.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.